Multimodal Prediction of Progression Toward Brain Death After Out-of-Hospital Cardiac Arrest

Jae Hun Oh1, Jisu Kim1, Jong Ho Zhu1

  • 1Department of Emergency, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 03312, Republic of Korea.

Insights

A new multimodal model predicts progression toward brain death (PTBD) in severe hypoxic-ischemic brain injury patients after cardiac arrest. This model combines CT scans, serum markers, and clinical data for early risk stratification.

Area of Science:

  • Neurology
  • Critical Care Medicine
  • Radiology

Background:

  • Severe hypoxic-ischemic brain injury following out-of-hospital cardiac arrest (OHCA) can lead to brain death.
  • Conventional neurological outcome classifications do not adequately capture this trajectory.
  • A multimodal approach is needed for accurate prediction.

Purpose of the Study:

  • To develop and evaluate a multimodal model to predict progression toward brain death (PTBD).
  • The model integrates quantitative brain CT, serum neuron-specific enolase (NSE), and clinical variables.
  • To assess the model's performance in predicting PTBD within 48 hours.

Main Methods:

  • Retrospective analysis of prospectively collected data from the Korean Hypothermia Network registry.
  • Inclusion of comatose OHCA survivors treated with targeted temperature management.
  • Development of multivariable logistic regression models and internal validation using discrimination, calibration, and Brier score.

Main Results:

  • The multimodal model demonstrated strong predictive performance (AUC 0.895, corrected AUC 0.890 in the total cohort).
  • Key predictors included younger age, non-shockable rhythm, low gray-to-white matter ratio (GWR), and higher NSE at 48h.
  • The model significantly outperformed individual predictors in the poor-outcome subgroup.

Conclusions:

  • Progression toward brain death (PTBD) is a distinct clinical trajectory in OHCA patients.
  • The developed multimodal model shows promising internal validation for early risk stratification.
  • Further external validation is necessary before clinical implementation for neuroprognostication.